September 2021 Content Release Copied

09/30/20212021 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation Additions

The following items are available for documentation in Problems and appear on the Charge Capture Report

(CCR). NOTE: Additional ICD10 codes may display to present the surrounding nodes.

Problem	ICD10 Code Choice(s)*
Antineoplastic chemotherapy regimen	Z51.11 – Encounter for antineoplastic chemotherapy
Ovarian Cancer	C56.1 – Malignant neoplasm of right ovary C56.2 – Malignant neoplasm of left ovary C56.3 – Malignant neoplasm of bilateral ovaries C56.9 – Malignant neoplasm of unspecified ovary C79.82 – Secondary malignant neoplasm of genital organs

Problem

ICD10 Code Choice(s)*

Antineoplastic chemotherapy regimen

Z51.11 – Encounter for antineoplastic chemotherapy

Ovarian Cancer

C56.1 – Malignant neoplasm of right ovary C56.2 – Malignant neoplasm of left ovary

C56.3 – Malignant neoplasm of bilateral ovaries C56.9 – Malignant neoplasm of unspecified ovary

C79.82 – Secondary malignant neoplasm of genital organs

Lab Analyte, Panel and Service Additions and Updates

17-OH progesterone panel
Amyloidosis DNA sequence comment
B2 microglobulin, CSF
B2 microglobulin, CSF panel
Campylobacter SPP. AG,EIA
Coccidioides Ab to F antigen(IgG), ID
Coccidioides Ab to TP antigen(IgM), ID
Colorectal cancer screening; blood-based biomarker
Donor, HBV, NAT discriminatory
dRVVT screen ratio
Fine needle aspirate
Fine needle aspirate panel
Flow cytometry report
Guardant reveal panel
Guardant reveal, sendouts
JO-1 Ab, SI
Plts Agree?
Prostate specific Ag (diagnostic) panel
Prostate specific Ag (diagnostic), ng/mL
Thyroglobulin, LC/MS/MS panel
TIF-1y Ab, SI
TPA antigen, ng/mL
TPMT activity, nmol/hr/mL RBC
Vedolizumab interpretation

Medications

Additions

BDTX-189 invest Oral
Belzutifan Oral
Cryoprecipitated Fibrinogen Complex, Pathogen Reduced
DF6002 invest Subcutaneous
Fresh Frozen Plasma Between 8-24 Hours of Collection
M1774 invest Oral
NBF-006 invest Intravenous
NIS793 invest Intravenous
Plasma, Cryoprecipitate Reduced, Pathogen Reduced
Platelets, Leukocytes Reduced, CMV-Negative, Apheresis/Pheresis
Platelets, Pheresis, Leukocytes Reduced, CMV- Negative, Irradiated
Platelets, Pheresis, Leukocytes Reduced, Irradiated
Platelets, Pheresis, Pathogen-Reduced
Red Blood Cells, Deglycerolized<
Red Blood Cells, Leukocytes Reduced, CMV- Negative, Irradiated
STI-6643 invest Intravenous
Sym021 invest IV
TJ004309 invest Intravenous
Whole Blood or Red Blood Cells, Leukocytes Reduced, CMV-negative

Updates

The billing and administration boxes are is now checked for the following terms:

Fresh Frozen Plasma
Whole Blood
Platelets, Leukopoor, Irradiated
Platelets, Leukopoor
Platelets, Pheresis, Leukopoor, Irradiated
Platelets, Non-irradiated
HLA Matched Platelets, 1 unit

Drug Name	Updates
Hydrocodone-Acetaminophen Oral Liquid 7.5 mg-325 mg/15 mL	Updated default Sig: 15 mL orally every 4 hours prn pain
KTR-255 invest IV	Added Form: 1 mg intravenous solution
NKTR-255 invest IV	Added Form: 1 mg intravenous solution
NBTXR3 invest Intratumoral	Added Sigs: 0 g/L intratumorally once 0 mL intratumorally once
Oxycodone Oral Liquid	Updated default Sig: 0.25 mL by mouth every 4 to 6 hours prn pain
Polystyrene Oral Suspension	Updated default Sig: 60 mL orally daily

Regimens

This section does not include clinical trials.

Additions

Anifrolumab-fnia Q28D
Belzutifan Q30D
Pembrolizumab + Doxorubicin + Cyclophosphamide (AC) Q21D fb Pembrolizumab + Paclitaxel D1,8,15 + Carboplatin D1,8,15 Q21D
Pembrolizumab Q42D (Flat Dose, Adjuvant Breast)
Pembrolizumab + Low-Dose Ipilimumab Q21D

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

All Problems
Amyloidosis
Bile Duct Cancer (Parent)
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Esophageal Cancer (Parent)
Gallbladder Cancer
Gestational Trophoblastic Tumor
Leukemia, Acute Myeloid (AML)
Leukemia, Chronic Lymphocytic (CLL)
Leukemia, Chronic Myelomonocytic (CMML)
Lung Cancer, Non-small Cell (NSCLC)
Lymphoma, Non-Hodgkin (NHL) (Parent)
Melanoma, Skin
Multiple Myeloma (MM)
Myelodysplastic Syndrome (MDS)
Rectal Cancer
Renal Pelvis and Ureter Cancer
Urethral Cancer

Removal

Docetaxel Q21D (Gastric)

Renames

Previous Name	New Name
Azacitidine SQ 5-2-2 Q28D	Azacitidine SQ D1-5,8-9 Q28D
Daratumumab + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction C1 Split Dosing)	Daratumumab IV + Bortezomib + Thalidomide + Dexamethasone Q28D (Part 1 of 2: Induction C1 Split Dosing)
Fluorouracil Bolus D1,4 + Doxorubicin D1 + Cyclophosphamide D1 (FAC) Q21D	Fluorouracil Bolus D1,4 + Doxorubicin + Cyclophosphamide (FAC) Q21D
Lenalidomide (MCL)	Lenalidomide D1-21 Q28D (NHL)
Lenalidomide D1-21 + Dexamethasone D1-4,15- 18 Q28D (Amyloidosis)	Lenalidomide D1-21 + Dexamethasone Q28D (Amyloidosis)
Lenalidomide (CLL)	Lenalidomide Q28D (CLL)
Lenalidomide (MDS)	Lenalidomide Q28D (MDS)
Nivolumab Q14D (Dose Banding) (Adjuvant Melanoma, Esophageal)	Nivolumab Q14D (Dose Banding) (Adjuvant Melanoma, Esophageal, Bladder)
Nivolumab Q14D (Flat Dose) (Adjuvant Melanoma, Esophageal)	Nivolumab Q14D (Flat Dose) (Adjuvant Melanoma, Esophageal, Bladder)
Nivolumab Q28D (Dose Banding) (Adjuvant Melanoma, Esophageal)	Nivolumab Q28D (Dose Banding) (Adjuvant Melanoma, Esophageal, Bladder)
Nivolumab Q28D (Flat Dose) (Adjuvant Melanoma, Esophageal)	Nivolumab Q28D (Flat Dose) (Adjuvant Melanoma, Esophageal, Bladder)

Research

Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes<
USOR 18187	X		X
USOR 18283	X	X		The following regimens are now available for ordering: USOR 18283 Cisplatin D1 + Sacituzumab Govitecan D1,8 Q21D USOR 18283 Cisplatin (split dose) D1,8 + Sacituzumab Govitecan D1,8 Q21D USOR 18283 Cisplatin D1 + Sacituzumab Govitecan D1,8 Q21D + Avelumab Q14D USOR 18283 Cisplatin (split dose) D1,8 + Sacituzumab Govitecan D1,8 Q21D + Avelumab Q14D USOR 18283 Avelumab D1,15,29 + Sacituzumab Govitecan D1,8,22,29 Q42D (Maintenance Therapy) The following regimen is no longer available for ordering: USOR 18283 Sacituzumab Govitecan (IMMU-132) D1,8 + Pembrolizumab D1 Q21D
USOR 19001	X	X	X
USOR 19174	X	X
USOR 19241	X	X	X
USOR 19247	X
USOR 20137	X	X	X
USOR 20150	X	X	X
USOR 20176	X			The following regimen is now available for ordering: USOR 20176 Group E Epacadostat (PO; BID) + INCMGA00012 Q28D
USOR 20249		X
USOR 20257	X	X
USOR 20285	X		X
USOR 20308	X			The following regimens are now available for ordering: USOR 20308 Part 2 Group A: Sotorasib (PO; Daily) + Afatinib (PO; Daily) Q21D USOR 20308 Part 2 Group B: Sotorasib (PO; Daily) + Afatinib (PO; Daily) Q21D
USOR 20310	X	X	X
USOR 20318	X	X	X
USOR 20402	X
USOR 20430	X	X

Billing: HCPCS Codes

Updates

For a complete list of October 1, 2021 (and other) HCPCS updates, please visit CMS HCPCS Quarterly Update and for complete list of October 2021 ICD-10 updates, please visit CMS 2022 ICD-10-CM.

Non-Medication Code: G0327 Colorectal cancer screening; blood-based biomarker

Medication Name	HCPCS Code
Casimersen IV	J1426 per 10 mg
Casirivimab-Imdevimab IV 60 mg-60 mg/mL (EUA)	Q0240 per 600 mg Q0244 per 1200 mg
Casirivimab-Imdevimab Subcutaneous 60 mg-60 mg/mL (EUA)	Q0240 per 600 mg Q0244 per 1200 mg
Cefiderocol IV	J0699 per 10 mg
Cryoprecipitated Fibrinogen Complex, Pathogen Reduced	P9026 per 1 Units
Etonogestrel-Ethinyl Estradiol Vaginal Ring 0.12 mg-0.015 mg/24 hr	J7295 per 1 vaginal ring
Evinacumab-dgnb IV	J1305 per 5 mg
Ferric Pyrophosphate Citrate Hemodialysis 27.2 mg iron/5 mL	J1445 per 0.1 mg
Fresh Frozen Plasma Between 8-24 Hours of Collection	P9059 per 1 Units
Influenza Virus Vaccine IM Quad-Split (6 months & older), 0.5 mL	90688 per 0.5 mL
Influenza Virus Vaccine IM Quad-Split (6 months & older), 0.25 mL	90687 per 0.25 mL
Influenza Virus Vaccine (PF) IM Quad-Split (6 months & older), 0.5 mL	90686 per 0.5 mL
Lisocabtagene Maraleucel IV	Q2054 per 1x10e6 CARpos viabl T cells
Melphalan Flufenamide IV	J9247 per 1 mg
Oritavancin IV	J2406 per 10 mg
Plasma, Cryoprecipitate Reduced, Pathogen Reduced	P9025 per 1 Units
Platelets, Leukocytes Reduced, CMV-Negative, Apheresis/Pheresis	P9055 per 1 Units
Platelets, Pheresis, Leukocytes Reduced, CMV-Negative, Irradiated	P9053 per 1 Units
Platelets, Pheresis, Leukocytes Reduced, Irradiated	P9035 per 1 Units
Platelets, Pheresis, Pathogen-Reduced	P9073 per 1 Units
Pneumococcal 15-Val Conj-Dip Crm (PF) IM	90671 per 0.5 mL
Red Blood Cells, Deglycerolized – P9039	P9039 per 1 Units
Red Blood Cells, Leukocytes Reduced, CMV-Negative, Irradiated	P9058 per 1 Units
Romidepsin IV	J9318 per 0.1 mg J9319 per 0.1 mg
Samarium Sm 153 Lexidronam IV	A9604 per 1 mCi
Segesterone AC-Ethin Estradiol Vaginal Ring 0.15mg-0.013 mg/24hr	J7294 per vaginal ring
Selexipag IV	J3490 per 1800 mcg
Trilaciclib IV	J1448 per 1 mg
Whole Blood or Red Blood Cells, Leukocytes Reduced, CMV-negative	P9051 per 1 Units

Procedures

The following procedures have been retired with the latest update. Order sets will need to be updated to replace retired concepts.

Procedure Name	Procedure Name
Adrenalectomy of remaining gland	Fluoroscopic venography of hepatic vein using contrast
Alexander exercises	Fluoroscopy guided percutaneous transluminal embolization of uterine artery
Amniocentesis with complication, without blame	Imaging of arteries of extremities
Angiography of arteries of extremity	Internal fixation of mandible with arch bars
Angiography of arteries of extremity with serialography	Laparoscopic nephrectomy of remaining kidney
Asthma severity	Laparoscopic nephrectomy of remaining kidney by retroperitoneal approach
Bilateral removal of ovo-testis	Ligation of fallopian tubes with division by endoscopy
Cholecystokinin measurement	Nephrectomy of remaining kidney
Controlled atelectasis	Nephrectomy of remaining or solitary kidney
CT angiography of pelvis and lower limb	Open clipping of remaining solitary fallopian tube
CT angiography of pulmonary artery	Open division of unilateral tendon of hamstring muscle
CT of abdominal aorta	Open ligation of remaining solitary fallopian tube
CT of thoracic aorta	Open ringing of remaining solitary fallopian tube
Cystourethroplasty with unilateral ureteroneocystostomy	Open unilateral transposition of subclavian artery to carotid artery with endovascular repair of descending thoracic aorta by neck incision
Cystourethroscopy with unilateral ureteral meatotomy	Operation on two or more extraocular muscles involving temporary detachment from globe, one or both eyes
Embolization of uterine fibroid using fluoroscopic guidance	Operation on two or more extraocular muscles, one or both eyes
Endoscopic insertion of tubal prosthesis into lower bowel using fiberoptic sigmoidoscope	Orchiectomy of remaining testis
Endoscopic occlusion of remaining left fallopian tube using intrafallopian implant	Partial glossectomy with unilateral radical neck dissection
Endoscopic occlusion of remaining right fallopian tube using intrafallopian implant	Standard ECG
Endoscopic occlusion of remaining solitary fallopian tube	Thermal vestibular function
Excision or destruction of orbital lesion	Venography of adrenal
Fallopian tube destruction/occlusion
Fluoroscopic angiography of aortic arch